Breast care | |
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer | |
Andreas D. Hartkopf1  | |
关键词: Breast cancer; Immunotherapy; PD-1; PD-L1; Clinical trials; | |
DOI : 10.1159/000453569 | |
学科分类:泌尿医学 | |
来源: S Karger AG | |
【 摘 要 】
Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201902018306282ZK.pdf | 907KB | download |